Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: PD-L1, . Treffer: 35

2023

Brcic, I; Kluba, AM; Godschachner, TM; Suppan, C; Regitnig, P; Dandachi, N; Lax, SF; Balić, M Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Int J Mol Sci. 2023; 24(1): Doi: 10.3390/ijms24010818 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Dai, Q; Zhang, J; Long, W; Haybaeck, J; Yang, Z Genetic alterations of GI-NECs involving three main signaling pathways.
Cancer Med. 2023; Doi: 10.1002/cam4.5633 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2022

Brcic, L; Savic, Prince, S [Predictive immunocytochemistry in non-small cell lung carcinoma].
PATHOLOGE. 2022; 43(3): 222-228. Doi: 10.1007/s00292-022-01066-4 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Illini, O; Fabikan, H; Hochmair, MJ; Weinlinger, C; Krenbek, D; Brcic, L; Setinek, U; Terbuch, A; Absenger, G; Konjić, S; Valipour, A Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study.
J Clin Med. 2022; 11(14): Doi: 10.3390/jcm11144098 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Lindner, AK; Pichler, M; Thurnher, M; Pichler, R Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma.
Eur Urol. 2022; 81(1): 1-2. Doi: 10.1016/j.eururo.2021.10.025
Web of Science PubMed FullText FullText_MUG

 

Plass, M; Dacic, S; Kern, I; Zacharias, M; Popper, H; Fukuoka, J; Kargl, M; Muller, H; Murauer, C; Brcic, L A Comparative Study of PD-L1 Scoring: Humans versus AI
J THORAC ONCOL. 2022; 17(9): S515-S515. [Poster]
Web of Science

 

Prinz, F; Jonas, K; Balihodzic, A; Klec, C; Reicher, A; Barth, DA; Riedl, J; Gerger, A; Kiesslich, T; Mayr, C; Rinner, B; Kargl, J; Pichler, M MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response.
RNA Biol. 2022; 19(1):1305-1315 Doi: 10.1080/15476286.2022.2152978 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2021

Brcic, L; Klikovits, T; Megyesfalvi, Z; Mosleh, B; Sinn, K; Hritcu, R; Laszlo, V; Cufer, T; Rozman, A; Kern, I; Mohorcic, K; Jakopovic, M; Samarzija, M; Seiwerth, S; Kolek, V; Fischer, O; Jakubec, P; Škarda, J; Gieszer, B; Hegedus, B; Fillinger, J; Renyi-Vamos, F; Buder, A; Bilecz, A; Berger, W; Grusch, M; Hoetzenecker, K; Klepetko, W; Hoda, MA; Filipits, M; Dome, B Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study.
Transl Lung Cancer Res. 2021; 10(4): 1594-1607. Doi: 10.21037/tlcr-20-1114 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Jabkowski, J; Loidl, A; Auinger, B; Kehrer, H; Sepp, N; Pichler, R Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report.
Front Immunol. 2021; 12: 606056 Doi: 10.3389/fimmu.2021.606056 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Smolle, MA; Herbsthofer, L; Granegger, B; Goda, M; Brcic, I; Bergovec, M; Scheipl, S; Prietl, B; Pichler, M; Gerger, A; Rossmann, C; Riedl, J; Tomberger, M; López-García, P; El-Heliebi, A; Leithner, A; Liegl-Atzwanger, B; Szkandera, J T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study.
Br J Cancer. 2021; 125(5):717-724 Doi: 10.1038/s41416-021-01456-0 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Zeisbrich, M; Chevalier, N; Sehnert, B; Rizzi, M; Venhoff, N; Thiel, J; Voll, RE CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
Front Immunol. 2021; 12:673912 Doi: 10.3389/fimmu.2021.673912 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Zhou, Y; Bastian, IN; Long, MD; Dow, M; Li, W; Liu, T; Ngu, RK; Antonucci, L; Huang, JY; Phung, QT; Zhao, XH; Banerjee, S; Lin, XJ; Wang, H; Dang, B; Choi, S; Karin, D; Su, H; Ellisman, MH; Jamieson, C; Bosenberg, M; Cheng, Z; Haybaeck, J; Kenner, L; Fisch, KM; Bourgon, R; Hernandez, G; Lill, JR; Liu, S; Carter, H; Mellman, I; Karin, M; Shalapour, S Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation.
Proc Natl Acad Sci U S A. 2021; 118(8): Doi: 10.1073/pnas.2025840118 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2020

Brcic, I; Gallob, M; Schwantzer, G; Zrnc, T; Weiland, T; Thurnher, D; Wolf, A; Brcic, L Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
Oral Oncol. 2020; 106: 104719-104719. Doi: 10.1016/j.oraloncology.2020.104719
Web of Science PubMed FullText FullText_MUG

 

Dummer, R; Lebbé, C; Atkinson, V; Mandalà, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HA; Ascierto, PA; Ribas, A; Flaherty, KT; Pakhle, N; Campbell, CD; Gusenleitner, D; Masood, A; Brase, JC; Gasal, E; Long, GV Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Nat Med. 2020; 26(10): 1557-1563. Doi: 10.1038/s41591-020-1082-2
Web of Science PubMed FullText FullText_MUG

 

Harter, P; Pautier, P; Van Nieuwenhuysen, E; Reuss, A; Redondo, A; Lindemann, K; Kurzeder, C; Petru, E; Heitz, F; Sehouli, J; Degregorio, N; Wimberger, P; Burges, A; Cron, N; Ledermann, J; Lorusso, D; Paoletti, X; Marme, F Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Int J Gynecol Cancer. 2020; 30(12): 1997-2001. Doi: 10.1136/ijgc-2020-001572
Web of Science PubMed FullText FullText_MUG

 

Mir, Seyed, Nazari, P; Berghoff, AS; Preusser, M; Moik, F; Posch, F; Ricken, G; Riedl, J; Hell, L; Marosi, C; Hainfellner, JA; Pabinger, I; Ay, C Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma.
ESMO Open. 2020; 5(3):e000647 Doi: 10.1136/esmoopen-2019-000647 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Riedl, JM; Barth, DA; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoeger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Posch, F C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Cancers (Basel). 2020; 12(8): Doi: 10.3390/cancers12082319 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Smolle, E; Leithner, K; Olschewski, H Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.
Thorac Cancer. 2020; 11(2):205-215 Doi: 10.1111/1759-7714.13246 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Suppan, C; Balic, M Treatment options in early triple-negative breast cancer Update from the San Antonio Breast Cancer Symposium 2019.
MEMO-MAG EUR MED ONC. 2020; Doi: 10.1007/s12254-020-00609-w [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

2019

Pichler, R; Compérat, E; Klatte, T; Pichler, M; Loidl, W; Lusuardi, L; Schmidinger, M Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?
Cancers (Basel). 2019; 11(3): 422 Doi: 10.3390/cancers11030422 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Riethdorf, S; Hildebrandt, L; Heinzerling, L; Heitzer, E; Fischer, N; Bergmann, S; Mauermann, O; Waldispühl-Geigl, J; Coith, C; Schön, G; Peine, S; Schuler, G; Speicher, MR; Moll, I; Pantel, K Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma.
CLIN CHEM. 2019; 65(3): 462-472. Doi: 10.1373/clinchem.2018.297028
Web of Science PubMed FullText FullText_MUG

 

Smolle, MA; Prinz, F; Calin, GA; Pichler, M Current concepts of non-coding RNA regulation of immune checkpoints in cancer.
Mol Aspects Med. 2019; 70:117-126 Doi: 10.1016/j.mam.2019.09.007
Web of Science PubMed FullText FullText_MUG

 

van Seijen, M; Brcic, L; Gonzales, AN; Sansano, I; Bendek, M; Brcic, I; Lissenberg-Witte, B; Korkmaz, HI; Geiger, T; Kammler, R; Stahel, R; Thunnissen, E; ETOP Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen.
Virchows Arch. 2019; 475(2):191-199 Doi: 10.1007/s00428-019-02595-9 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Walsh, NM; Castonguay, MC; Carter, MD; Pasternak, S; Ly, TY; Doucette, S; Hanly, JG; Saggini, A; Cerroni, L Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
Am J Dermatopathol. 2019; 41(11):819-825 Doi: 10.1097/DAD.0000000000001390
Web of Science PubMed FullText FullText_MUG

 

2018

Carlino, MS; Long, GV; Schadendorf, D; Robert, C; Ribas, A; Richtig, E; Nyakas, M; Caglevic, C; Tarhini, A; Blank, C; Hoeller, C; Bar-Sela, G; Barrow, C; Wolter, P; Zhou, H; Emancipator, K; Jensen, EH; Ebbinghaus, S; Ibrahim, N; Daud, A Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
EUR J CANCER. 2018; 101(3): 236-243. Doi: 10.1016/j.ejca.2018.06.034 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gandhi, L; Rodríguez-Abreu, D; Gadgeel, S; Esteban, E; Felip, E; De Angelis, F; Domine, M; Clingan, P; Hochmair, MJ; Powell, SF; Cheng, SY; Bischoff, HG; Peled, N; Grossi, F; Jennens, RR; Reck, M; Hui, R; Garon, EB; Boyer, M; Rubio-Viqueira, B; Novello, S; Kurata, T; Gray, JE; Vida, J; Wei, Z; Yang, J; Raftopoulos, H; Pietanza, MC; Garassino, MC; KEYNOTE-189 Investigators Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med. 2018; 378(22): 2078-2092. Doi: 10.1056/NEJMoa1801005
Web of Science PubMed FullText FullText_MUG

 

Zaric, B; Brcic, L; Buder, A; Brandstetter, A; Buresch, JO; Traint, S; Kovacevic, T; Stojsic, V; Perin, B; Pirker, R; Filipits, M PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.
Clin Lung Cancer. 2018; 19(6):e957-e963-e957-e963 Doi: 10.1016/j.cllc.2018.08.014
Web of Science PubMed FullText FullText_MUG

 

Zhou, XA; Louissaint, A; Wenzel, A; Yang, J; Martinez-Escala, ME; Moy, AP; Morgan, EA; Paxton, CN; Hong, B; Andersen, EF; Guitart, J; Behdad, A; Cerroni, L; Weinstock, DM; Choi, J Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
J INVEST DERMATOL. 2018; 138(11): 2365-2376. Doi: 10.1016/j.jid.2018.04.038 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Smolle, MA; Calin, HN; Pichler, M; Calin, GA Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.
FEBS J. 2017; 284(13):1952-1966 Doi: 10.1111/febs.14030 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Walsh, NM; Fleming, KE; Hanly, JG; Dakin Hache, K; Doucette, S; Ferrara, G; Cerroni, L A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma.
Hum Pathol. 2016; 52(6):190-196 Doi: 10.1016/j.humpath.2016.02.002
Web of Science PubMed FullText FullText_MUG

 

2015

Mischinger, J; Comperat, E; Schwentner, C; Stenzl, A; Gakis, G Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?
Curr Urol Rep. 2015; 16(9):59-59 Doi: 10.1007/s11934-015-0532-8
Web of Science PubMed FullText FullText_MUG

 

2014

Becker, JC; thor Straten, P; Andersen, MH Self-reactive T cells: suppressing the suppressors.
Cancer Immunol Immunother. 2014; 63(4):313-319 Doi: 10.1007/s00262-013-1512-9
Web of Science PubMed FullText FullText_MUG

 

Rong, Z; Wang, M; Hu, Z; Stradner, M; Zhu, S; Kong, H; Yi, H; Goldrath, A; Yang, YG; Xu, Y; Fu, X An effective approach to prevent immune rejection of human ESC-derived allografts.
Cell Stem Cell. 2014; 14(1):121-130 Doi: 10.1016/j.stem.2013.11.014 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Kronsteiner, B; Wolbank, S; Peterbauer, A; Hackl, C; Redl, H; van Griensven, M; Gabriel, C Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells.
Stem Cells Dev. 2011; 20(12): 2115-2126. Doi: 10.1089/scd.2011.0031
Web of Science PubMed FullText FullText_MUG

 

2003

Petroff, MG; Chen, L; Phillips, TA; Azzola, D; Sedlmayr, P; Hunt, JS B7 family molecules are favorably positioned at the human maternal-fetal interface.
Biol Reprod. 2003; 68(5):1496-1504 Doi: 10.1095/biolreprod.102.010058 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum